Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

The addition of high-dose cytarabine to rituximab/bendamustine (RB) induction could improve outcomes for transplant-eligible patients with mantle cell lymphoma (MCL). We conducted a pooled analysis of 2 phase 2 trials and an off-trial cohort each testing 3 cycles of RB and 3 cycles of rituximab/high...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Merryman, Reid W., Edwin, Natasha, Redd, Robert, Bsat, Jad, Chase, Matthew, LaCasce, Ann, Freedman, Arnold, Jacobson, Caron, Fisher, David, Ng, Samuel, Crombie, Jennifer, Kim, Austin, Odejide, Oreofe, Davids, Matthew S., Brown, Jennifer R., Jacene, Heather, Cashen, Amanda, Bartlett, Nancy L., Mehta-Shah, Neha, Ghobadi, Armin, Kahl, Brad, Joyce, Robin, Armand, Philippe, Jacobsen, Eric
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2020
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065472/
https://ncbi.nlm.nih.gov/pubmed/32126141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001355
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki